Research Progress on the Mechanism, Monitoring, and Prevention of Cardiac Injury Caused by Antineoplastic Drugs-Anthracyclines

• Published in: Biology (Basel, Switzerland) Vol. 13; no. 9; p. 689
• Main Authors: Chen, Yuanyuan, Yang, Wenwen, Cui, Xiaoshan, Zhang, Huiyu, Li, Liang, Fu, Jianhua, Guo, Hao
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.09.2024
• Subjects: Anthracycline; Anthracyclines; Antineoplastic drugs; Apoptosis; Autophagy; Cancer; Cancer therapies; Cardiac arrhythmia; Cardiomyocytes; Cardiomyopathy; Cardiotoxicity; Cell death; Chemotherapy; Drug development; Drug therapy; Ferroptosis; Gastrointestinal diseases; Heart; Heart failure; Homeostasis; Lipid peroxidation; Lymphoma; Lymphomas; Malignancy; mechanisms; Medical imaging equipment; Microenvironments; Mitochondria; Mitochondrial DNA; Molecular modelling; monitoring; Mortality; Nanoparticles; Nitric oxide; Oxidative stress; Pathogenesis; Patients; Permeability; Pluripotency; prevention; Quality of life; Stem cells; treatment; treatment; cardiotoxicity; anthracyclines; monitoring; mechanisms; prevention
• ISSN: 2079-7737; 2079-7737
• DOI: 10.3390/biology13090689

Anthracyclines represent a highly efficacious class of chemotherapeutic agents employed extensively in antitumor therapy. They are universally recognized for their potency in treating diverse malignancies, encompassing breast cancer, gastrointestinal tumors, and lymphomas. Nevertheless, the accumulation of anthracyclines within the body can lead to significant cardiac toxicity, adversely impacting both the survival rates and quality of life for tumor patients. This limitation somewhat restricts their clinical utilization. Determining how to monitor and mitigate their cardiotoxicity at an early stage has become an urgent clinical problem to be solved. Therefore, this paper reviews the mechanism of action, early monitoring, and strategies for the prevention of anthracycline-induced cardiotoxicity for clinical reference.